Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCI | P41743 | 2/20 | 0.38 |
| ▸ | BRAF | P15056 | 5/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
| ▸ | BCR | P11274 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14138580 | 0.82 | CACNA1H (0.43) | BRAFPKMALDH1A1 | |
| SCHEMBL13167789 | 0.80 | PKM (0.56) | BRAFPKM | |
| SCHEMBL14138576 | 0.80 | HPGD (0.43) | BRAFPKMALDH1A1 | |
| SCHEMBL14138527 | 0.77 | PKM (0.36) | BRAFPKM | |
| SCHEMBL14138705 | 0.75 | SCD (0.40) | BRAFALDH1A1 | |
| SCHEMBL14138603 | 0.75 | PKM (0.37) | BRAFPKM | |
| SCHEMBL14138708 | 0.73 | PKM (0.38) | BRAFCHEK1PKM | |
| SCHEMBL14138578 | 0.73 | CYP2C9 (0.41) | BRAFABL1ALDH1A1 | |
| SCHEMBL14138703 | 0.73 | ALDH1A1 (0.40) | BRAFPKMALDH1A1 | |
| SCHEMBL3584944 | 0.71 | PKM (0.59) | BRAFPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008079277-A1 | CERTAIN PYRAZOLINE DERIVATIVES WITH KINASE INHIBITORY ACTIVITY | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-07-03 | — | — | WO | disclosed |